Cogram, Patricia

NNZ-2566, a novel analog of (1–3) IGF-1, as a potential therapeutic agent for fragile X syndrome

Deacon, R. M. J., Glass, L., Snape, M., Hurley, M. J., Altimiras, F. J., Biekofsky, R. R., & Cogram, P. (2015) · NeuroMolecular Medicine

Genetics and Neurodevelopmental DisordersNeuroscience and Neuropharmacology Research

Cited by 78

Multiple behavior phenotypes of the fragile-X syndrome mouse model respond to chronic inhibition of phosphodiesterase-4D (PDE4D)

Gurney, M. E., Cogram, P., Deacon, R. M., Rex, C., & Tranfaglia, M. (2017) · Scientific Reports

Genetics and Neurodevelopmental DisordersPhosphodiesterase function and regulation

Cited by 69

Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy

Reyes, S. T., Deacon, R. M. J., Guo, S. G., Altimiras, F. J., Castillo, J. B., van der Wildt, B., Morales, A. P., Park, J. H., Klamer, D., Rosenberg, J., et al. (2021) · Scientific Reports

Genetics and Neurodevelopmental DisordersPharmacological Receptor Mechanisms and Effects

Cited by 22

Alteration of Fatty Acid Profile in Fragile X Syndrome

Abolghasemi, A., Carullo, M. P., Aguilera, E. C., Laroui, A., Plantefeve, R., Rojas, D., Benachenhou, S., Ramírez, M. V., Proteau-Lemieux, M., Lepage, J.-F., et al. (2022) · International Journal of Molecular Sciences

Fatty Acid Research and HealthGenetics and Neurodevelopmental Disorders

Cited by 6